Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLR: Simple Oral Therapy for Low Risk Breast Cancer
NCT03238703Phase 4Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2018
- Primary completion
- Mar 2023
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of anastrozole, exemestane, letrozole, tamoxifen, toremifene in breast cancer, sponsored by Fred Hutchinson Cancer Center. Planned start Sep 2018; status: withdrawn.
02
Drugs
anastrozoleexemestaneletrozoletamoxifentoremifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03238703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238703.